Strategy

We develop vaccines that address currently unmet medical needs. Our competitive edge comes from our proprietary Mimopath technology, which facilitates needle-free administration of vaccines into the mucosa, which raises a more natural immune response and provides a broader base of protection. With our positive proof-of-concept in Influenza completed, we’ve turned our focus to developing new and proprietary vaccine candidates such as SynGEM® and PneuGEM®. These programs build upon the successful development of a nasal vaccine using an improved formulation of existing (marketed) influenza vaccine. The FluGEM® program was leveraged as a proof-of-concept since it is well established how such influenza vaccines can be developed and how they provide protection, the development risks and costs of such vaccines are significantly reduced, and time to market is shortened.

07.11.16 Mucosis Initiates First-in-Human Study of SynGEM®, a Needle-Free Nasal Spray RSV Vaccine
more >

24.03.16 Mucosis to Present at World Vaccines Congress 2016
more >

20.01.16 Mucosis Secures €3.7M from Wellcome Trust to Fund Clinical Trials of its Respiratory Syncytial Virus Vaccine in Partnership with Imperial College London
more >

19.05.15 Mucosis to Present Data on Intranasal RSV Vaccine SynGEM® at Modern Vaccines Adjuvants & Delivery Systems 2015
more >

23.03.15 Mucosis to Present on Intranasal Respiratory Syncytial Virus Vaccine Candidate SynGEM® at BioCapital Europe
more >

10.11.14 Mucosis Presents Data on Intranasal Respiratory Syncytial Virus Vaccine SynGEM® at RSV2014 Symposium
more >

20.10.14 Mucosis Presents Data on Intranasal RSV Vaccine SynGEM® at Vaccines 2014 Conference
more >